Rheos Medicines Forms Research Collaboration with CRYOSTEM to Evaluate MALT1 Targeted Therapeutics for Graft-versus-Host-Disease
CAMBRIDGE, Mass., and MARSEILLE, France, October 27, 2021 – Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and inflammatory disease, today announced a research collaboration with the French non-profit research organization CRYOSTEM. The goal of the research collaboration is to provide biological resources from HSCT (Hematopoietic Stem Cell Transplantation) patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease (GvHD), based on functional immunologic profiling of patients and identification of molecular signatures for MALT1 activity. This collaboration supports a precision medicine approach to enable the treatment of GvHD, by defining the predominant metabolic pathways in the anabolic hub that drive key pathogenic pathways in GvHD patient subsets.